This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pediatrix Medical Stock Rallies 37.7% in 6 Months: More Room to Run?
by Zacks Equity Research
MD is expected to benefit from rising patient volumes, a favorable payer mix and streamlining initiatives.
Here's Why Ensign Group Can be a Smart Addition to Your Portfolio
by Zacks Equity Research
ENSG remains well-poised for growth on growing service revenues, an expanding healthcare portfolio and sufficient cash balance.
Here's Why Community Health's Florida Divestiture Matters
by Zacks Equity Research
Offloading the Punta Gorda facility is expected to remove uncertainty tied to restoration costs and revenue losses for CYH.
Wall Street Analysts Believe Pediatrix Medical Group (MD) Could Rally 25.5%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Pediatrix Medical Group (MD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MD or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. HQY: Which Stock Is the Better Value Option?
MD Gains 11% Since Q4 Earnings Release, Unveils '25 View
by Zacks Equity Research
Pediatrix Medical's fourth-quarter results reflect a declining overall expense level. It estimates 2025 net income to lie within $98.3-$112.9 million.
Pediatrix Medical Group (MD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 37.84% and 3.44%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Pediatrix Medical Gears Up for Q4 Results: What to Expect?
by Zacks Equity Research
MD's fourth-quarter results are likely to reflect declining revenues and expenses.
MD vs. AVTR: Which Stock Is the Better Value Option?
by Zacks Equity Research
MD vs. AVTR: Which Stock Is the Better Value Option?
Here's Why Pediatrix Medical Group (MD) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MD vs. AVTR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MD vs. AVTR: Which Stock Is the Better Value Option?
Should You Buy, Sell or Hold Pediatrix Medical Stock at a 9.28X P/E?
by Zacks Equity Research
Stable same-facility patient volume growth, inorganic initiatives and transition to an RCM structure should aid MD's future growth.
Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks?
by Zubia Masood
The Healthcare sector sees volume growth and improved occupancy while battling rising medical costs and regulatory uncertainty.
Molina Healthcare Expands Dual Eligible Services in Michigan, Idaho
by Zacks Equity Research
MOH secures key contracts in Michigan and Idaho to expand services for dual-eligible populations, driving growth and strengthening its role in integrated care solutions.
Ensign Group Rewards Shareholders With 4.2% Dividend Hike
by Zacks Equity Research
ENSG hikes quarterly dividend by 4.2%, maintaining its record of raising dividends for the past 22 years.
Why Pediatrix Medical Group (MD) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Centene Unveils Its 2025 Guidance, Reaffirms 2024 Outlook
by Zacks Equity Research
CNC expects robust growth in its Medicaid, Marketplace and Medicare businesses. This is likely to be driven by rate increases, rising uninsured individuals and dual expansions.
Community Health to Divest North Carolina Hospital for $280M
by Zacks Equity Research
CYH is selling the 123-bed facility in Mooresville to Duke Health.
MD or AVTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. AVTR: Which Stock Is the Better Value Option?
Brookdale's 37-Month Growth Streak: Is BKD Stock a Safe Bet?
by Zacks Equity Research
BKD's weighted average occupancy for November grows 10 bps sequentially.
Community Health Unit Northwest Urgent Closes Arizona Buyouts
by Zacks Equity Research
CYH's acquisition expands Northwest Healthcare arm's network to more than 80 care sites.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Despite Fast-paced Momentum, Pediatrix Medical Group (MD) Is Still a Bargain Stock
by Zacks Equity Research
Pediatrix Medical Group (MD) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
MD or AVTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MD vs. AVTR: Which Stock Is the Better Value Option?